Bisphosphonate Effects on Glucose Metabolism in Postmenopausal Women

Menopause is accompanied by a natural decline in oestrogen levels, leading to accelerated bone resorption and shifts in energy regulation. Bisphosphonates, a class of antiresorptive agents commonly prescribed for postmenopausal osteoporosis, inhibit osteoclast-mediated bone degradation by binding to mineralised bone surfaces. Beyond skeletal benefits, emerging evidence indicates that modulation of bone turnover affects systemic glucose metabolism. Osteoclasts secrete enzymes and cytokines that can degrade incretin hormones or influence insulin signalling in liver and muscle. By attenuating osteoclast activity, bisphosphonates may reduce the release of such factors, thereby enhancing circulating levels of insulin-stimulatory peptides and improving insulin sensitivity. Clinically, observational and interventional studies in postmenopausal women have reported modest improvements in glycaemic indices and a lower risk of incident type 2 diabetes among long-term bisphosphonate users. These dual actions on bone and metabolism hold significance for holistic care, particularly in ageing populations at risk of both osteoporosis and glucose intolerance.

Research from Nature Portfolio

Recent studies have identified specific coupling factors released by osteoclasts that link bone remodelling to energy homeostasis. Research employing selective blockade of osteoclast function revealed a marked reduction in circulating dipeptidyl peptidase-4 (DPP4), an enzyme that degrades incretins. The consequent rise in glucagon-like peptide-1 (GLP-1) levels enhanced postprandial insulin secretion and improved measures of glycaemic control. These findings establish a molecular pathway through which antiresorptive therapy may confer ancillary metabolic benefits alongside fracture prevention.

Bisphosphonate Effects on Glucose Metabolism in Postmenopausal Women publication trend

The graph below shows the total number of articles in bisphosphonate effects on glucose metabolism in postmenopausal women across all publications each year (not limited to Nature Index journals).

Technical terms

Bisphosphonates: Synthetic compounds that bind to bone mineral and inhibit osteoclast-mediated bone resorption.

Osteoclasts: Multinucleated cells responsible for bone matrix breakdown during remodelling.

Osteokines: Bone-derived signalling proteins that influence metabolism in distant organs.

Dipeptidyl Peptidase-4 (DPP4): An enzyme that degrades incretin hormones, reducing insulin secretion.

Glucagon-like Peptide-1 (GLP-1): An incretin hormone that potentiates glucose-dependent insulin release and improves glycaemic control.

References

1. Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nature Communications (2020).
2. The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News?. Journal of Clinical Medicine (2021).
3. The Use of Alendronate Is Associated with a Decreased Incidence of Type 2 Diabetes Mellitus—A Population-Based Cohort Study in Taiwan. PLOS ONE (2015).
4. Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study. Frontiers in Endocrinology (2021).